Teachers Retirement System of The State of Kentucky Increases Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

Teachers Retirement System of The State of Kentucky raised its stake in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 198.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 9,010 shares of the company's stock after buying an additional 5,989 shares during the period. Teachers Retirement System of The State of Kentucky's holdings in Krystal Biotech were worth $1,640,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also added to or reduced their stakes in the stock. Summit Trail Advisors LLC bought a new stake in shares of Krystal Biotech in the third quarter valued at about $1,893,000. Swiss National Bank increased its position in Krystal Biotech by 8.0% during the 3rd quarter. Swiss National Bank now owns 39,100 shares of the company's stock valued at $7,117,000 after purchasing an additional 2,900 shares during the period. Sei Investments Co. raised its holdings in shares of Krystal Biotech by 18.9% in the 2nd quarter. Sei Investments Co. now owns 40,115 shares of the company's stock valued at $7,367,000 after purchasing an additional 6,363 shares in the last quarter. Shaker Investments LLC OH purchased a new stake in shares of Krystal Biotech in the 3rd quarter worth approximately $532,000. Finally, Citigroup Inc. boosted its stake in shares of Krystal Biotech by 65.4% during the third quarter. Citigroup Inc. now owns 35,084 shares of the company's stock valued at $6,386,000 after purchasing an additional 13,874 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

KRYS has been the subject of a number of recent research reports. William Blair upgraded shares of Krystal Biotech to a "strong-buy" rating in a report on Friday, August 30th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Krystal Biotech in a research note on Thursday, August 29th. Citigroup increased their target price on shares of Krystal Biotech from $204.00 to $206.00 and gave the company a "neutral" rating in a research report on Tuesday, November 5th. Stifel Nicolaus lifted their price target on shares of Krystal Biotech from $204.00 to $220.00 and gave the stock a "buy" rating in a report on Wednesday, September 11th. Finally, HC Wainwright reiterated a "buy" rating and set a $221.00 price objective on shares of Krystal Biotech in a report on Wednesday. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $206.67.

Insider Buying and Selling

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm's stock in a transaction on Friday, December 13th. The stock was sold at an average price of $164.78, for a total value of $4,119,500.00. Following the transaction, the insider now owns 1,475,882 shares in the company, valued at approximately $243,195,835.96. This trade represents a 1.67 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 14.10% of the stock is currently owned by insiders.

Krystal Biotech Price Performance

NASDAQ:KRYS traded down $12.40 during trading hours on Wednesday, reaching $156.64. The company had a trading volume of 359,642 shares, compared to its average volume of 322,707. Krystal Biotech, Inc. has a 1-year low of $107.50 and a 1-year high of $219.34. The business's 50 day moving average price is $181.01 and its 200-day moving average price is $185.37. The firm has a market cap of $4.51 billion, a PE ratio of 88.50 and a beta of 0.80.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.07. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The firm had revenue of $83.84 million during the quarter, compared to analyst estimates of $82.94 million. During the same quarter in the previous year, the business earned ($0.67) EPS. Krystal Biotech's revenue for the quarter was up 879.9% compared to the same quarter last year. On average, analysts expect that Krystal Biotech, Inc. will post 2.97 earnings per share for the current fiscal year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).